PROMIS NEUROSCIENCES INC (PMN) Stock Price, Forecast & Analysis
USA - NASDAQ:PMN - CA74346M4065 - Common Stock
PMN Key Statistics, Chart & Performance
The current stock price of PMN is 0.379 USD. In the past month the price decreased by -22.65%. In the past year, price decreased by -64.58%.
PMN Latest News, Press Relases and Analysis
PMN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About PMN
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Company Info
PROMIS NEUROSCIENCES INC
Suite 200, 1920 Yonge Street
TORONTO ONTARIO CA
Employees: 8
Phone: 14168476898
PROMIS NEUROSCIENCES INC / PMN FAQ
What does PMN do?
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
What is the current price of PMN stock?
The current stock price of PMN is 0.379 USD. The price decreased by -2.99% in the last trading session.
Does PMN stock pay dividends?
PMN does not pay a dividend.
What is the ChartMill technical and fundamental rating of PMN stock?
PMN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is PROMIS NEUROSCIENCES INC (PMN) stock traded?
PMN stock is listed on the Nasdaq exchange.
Can you provide the market cap for PROMIS NEUROSCIENCES INC?
PROMIS NEUROSCIENCES INC (PMN) has a market capitalization of 20.39M USD. This makes PMN a Nano Cap stock.
Can you provide the short interest for PMN stock?
The outstanding short interest for PROMIS NEUROSCIENCES INC (PMN) is 0.5% of its float.
PMN Technical Analysis
PMN Financial Highlights
Over the last trailing twelve months PMN reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 88.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PMN Forecast & Estimates
8 analysts have analysed PMN and the average price target is 5.74 USD. This implies a price increase of 1413.85% is expected in the next year compared to the current price of 0.379.